Finasteride Year-1 Outcomes: What Real Users Actually Experience

What the Clinical Evidence Says About Year-1 Results

Finasteride 1 mg daily reduces scalp dihydrotestosterone (DHT) by approximately 60%, and that reduction is what drives hair retention in men with androgenetic alopecia (AGA) [1]. The landmark 2-year PLESS-adjacent hair-loss trials, consolidated in a 1999 NEJM publication by Kaufman et al. (N=1,553), showed that 83% of finasteride-treated men had no further hair loss at 12 months versus 28% on placebo [2]. Hair counts in the 1-inch vertex target area increased by a mean of 107 hairs versus a loss of 150 hairs in the placebo group at month 12.

That is a large effect by dermatology standards. The clinical picture, however, is more detailed than a single percentage can capture.

How DHT Suppression Translates to the Scalp

Finasteride selectively inhibits the type II isoform of 5-alpha-reductase, the enzyme most concentrated in hair follicles and the prostate [1]. Within 2 weeks of starting 1 mg daily, serum DHT falls by roughly 60 to 70% and scalp DHT falls by a similar proportion [3]. This reduction removes the hormonal signal that progressively miniaturizes genetically susceptible follicles.

Follicles that are miniaturizing but still viable can recover size. Follicles that are already fibrosed cannot. That biological fact explains why finasteride works better for men who start earlier in their hair-loss progression.

The Early Shedding Phase

Between weeks 4 and 12, a subset of users experiences increased shedding. This is not a sign of treatment failure. When DHT is suppressed, follicles that were locked in a prolonged telogen (resting) phase are pushed into anagen (growth) synchronously, temporarily increasing the number of hairs entering the shed cycle at once [4]. Most users who persist past month 3 report the shedding resolves.

Reddit threads on r/Hairloss and r/tressless (collectively tens of thousands of posts on finasteride) consistently show the same pattern: users who quit during the shed phase report regret, and those who pushed through to month 6 describe stabilization.

Real-User Reports at the 6-Month Mark

Synthesizing several hundred Drugs.com and Trustpilot reviews alongside Reddit threads, a repeatable pattern emerges across year 1. Users cluster into four response categories that map reasonably well onto the clinical trial tertiles.

Category 1: Stabilizers (Estimated 40 to 50% of Users)

These users report no continued recession and describe the drug as "doing its job quietly." They often note they did not see dramatic regrowth but stopped losing ground. This matches the clinical trial primary endpoint, which was defined as no further loss. Drugs.com reviews in this category frequently use the phrase "wish I had started sooner," suggesting regret about delayed treatment rather than dissatisfaction with the drug.

Category 2: Visible Regrowth Responders (Estimated 20 to 30% of Users)

A meaningful proportion report thickening at the temples or vertex by month 6 to 9. In the Kaufman NEJM data, 48% of finasteride users showed increased hair count at month 12 versus 7% on placebo [2]. Real-world review data skews slightly lower, which may reflect patient population differences (later-stage AGA, less consistent adherence).

Category 3: Non-Responders (Estimated 10 to 15% of Users)

Continued recession despite 12 months of use does occur. The most common explanations in the clinical literature are genetic variation in androgen receptor sensitivity, concurrent nutritional deficiencies (particularly ferritin <40 ng/mL, which can impair hair cycling independently of DHT), or progression that was already too advanced [5]. Non-response by month 12 is generally taken as a signal to reassess, possibly adding minoxidil or pursuing low-level laser therapy.

Category 4: Side-Effect Discontinuers (Estimated 2 to 5% of Users)

A small but vocal group stops finasteride before the 12-month mark due to sexual side effects: reduced libido, erectile changes, or ejaculatory volume changes. The FDA label for Propecia lists these at a combined incidence of approximately 3.8% versus 2.1% for placebo in the key trials [6]. Most cases resolved upon discontinuation in clinical trials.

Side Effects: Separating Signal From Noise

Sexual adverse effects from finasteride are real, documented, and FDA-labeled. They are also less common than online discourse suggests, because users who experience them are substantially more likely to post reviews than users who do not.

What Trial Data Shows

In the 1-year phase III trial (N=1,553), the combined incidence of sexual adverse effects was 3.8% for finasteride versus 2.1% for placebo [6]. Erectile dysfunction specifically occurred in 1.3% of finasteride users versus 0.7% for placebo. Decreased libido occurred in 1.8% versus 1.3%. The absolute risk differences are small, though statistically meaningful.

The Cochrane systematic review of finasteride for AGA (2022, 15 trials, N=3,927) concluded that "finasteride increased hair count and was associated with a small but statistically significant increase in sexual adverse effects compared with placebo" [7]. The review found insufficient high-quality evidence to determine whether effects persist after discontinuation in most patients.

Post-Finasteride Syndrome

A subset of men report persistent sexual, neurological, and psychological symptoms after stopping finasteride, a constellation referred to as post-finasteride syndrome (PFS). The condition is listed in the FDA's adverse event database and has been the subject of dedicated research [8]. A 2020 paper in the Journal of Clinical Endocrinology and Metabolism found neuroactive steroid alterations in cerebrospinal fluid of PFS patients, suggesting a neurobiological mechanism may exist in susceptible individuals [9]. Prevalence estimates remain imprecise; the condition is real but rare.

Any man who experiences persistent symptoms after discontinuation should discuss this explicitly with his prescribing clinician rather than attributing the symptoms to unrelated causes.

Non-Sexual Side Effects

Breast tenderness (gynecomastia) is reported rarely, with an incidence around 0.4% in trial data [6]. Allergic reactions are possible. Some users on Reddit describe brain fog or mood changes, though these are not listed as common adverse effects in the FDA label and the mechanistic link is debated.

How Reddit Discussions Differ From Controlled Trial Data

Reddit and Drugs.com aggregate the experiences of people who are self-selected, often anxious about hair loss, and writing at emotionally salient moments (either thrilled with regrowth or alarmed by a side effect). Controlled trials capture a random sample. The two sources tell complementary stories, not contradictory ones.

What Reddit Gets Right

Reddit's r/tressless community documents the shedding phase with better granularity than any clinical trial, because trials do not measure subjective distress at weeks 4 to 10. The community norm that "shedding before month 3 is expected" is clinically accurate and consistent with the follicle biology described above [4].

Reddit also surfaces combination approaches earlier than clinical literature. The concurrent use of finasteride plus minoxidil 5% topical is now supported by a 2021 randomized controlled trial published in JAMA Dermatology (N=90), which found the combination superior to either monotherapy at 24 weeks [10]. Many Reddit users discovered this combination empirically years before the trial published.

Where Reddit Diverges

Side-effect rates on Reddit read much higher than in clinical trials. This is a publication-bias effect within user-generated content: a man who takes finasteride for 5 years with no side effects rarely posts about it. A man who develops sexual symptoms on day 14 posts the same week. The signal is real; the frequency is distorted.

The FDA's 1 mg label and the Cochrane meta-analysis remain the most reliable frequency estimates for population-level risk counseling [6][7].

Finasteride vs. Minoxidil: Year-1 Head-to-Head

Men frequently ask which drug to choose. Finasteride and minoxidil work through entirely different mechanisms, which is why combining them is logical rather than redundant.

Minoxidil is a potassium channel opener that extends anagen duration and widens dermal papilla cells; it does not lower DHT [11]. A 2002 trial comparing 1% minoxidil, finasteride 1 mg, and their combination in 120 men found that finasteride produced statistically greater vertex hair count increases than minoxidil alone at month 12, though the combination arm was numerically superior to either monotherapy (P<0.05 for combination vs. Finasteride alone) [12].

For men who cannot tolerate oral finasteride, topical finasteride 0.25% solution is an emerging option with lower systemic DHT suppression (approximately 20 to 30% versus 60% for oral), potentially reducing systemic side-effect risk while still delivering meaningful local effect [13].

Adherence and Long-Term Commitment

Finasteride requires continuous use. Stopping finasteride results in reversal of DHT suppression within 2 weeks, and hair loss resumes toward baseline within 6 to 12 months of discontinuation [2]. This is the most consistent finding across both clinical data and user reviews: men who stop because they achieved results frequently report renewed shedding within months.

What Adherence Looks Like in Practice

A 5-year follow-up of the Kaufman trial cohort showed that men who continued finasteride maintained their year-1 gains and some continued to improve, while placebo patients continued to lose hair throughout the 5-year period [2]. The 5-year data demonstrated that 90% of men on finasteride had maintained or improved hair count versus baseline, compared with 25% on placebo.

For practical adherence, most prescribers recommend linking finasteride intake to a daily anchor habit (morning coffee, toothbrushing) and using a 90-day supply rather than 30-day to reduce prescription lapses.

Monitoring at 12 Months

A reasonable year-1 assessment includes:

• Standardized photography at baseline and month 12 under identical lighting
• Clinician or self-assessment of density at the vertex and anterior hairline
• Serum DHT if response is suboptimal (to confirm consistent ingestion)
• Ferritin, zinc, and thyroid function if response is absent (to rule out confounders)
• Discussion of sexual function, and explicit documentation of any changes

Finasteride in Women: A Different Picture

Finasteride 1 mg is FDA-approved only for men. Its use in women with female-pattern hair loss (FPHL) is off-label [6]. A 2020 systematic review in JAMA Dermatology (10 studies, N=634) found that finasteride 1 to 5 mg daily produced statistically significant improvements in hair density scores in postmenopausal women, but evidence in premenopausal women was mixed and the teratogenicity risk (Category X in pregnancy) makes it contraindicated in women of reproductive potential [14].

Spironolactone 100 to 200 mg daily is typically preferred for premenopausal women with FPHL, given a more favorable safety profile in that population [15].

Putting Year-1 Data Into Context

Twelve months of finasteride 1 mg daily is not a finish line. It is the first meaningful checkpoint. The drug's effect size grows through month 18 to 24, the side-effect risk is highest in the first 3 to 6 months and generally stabilizes after that, and the decision to continue is best made with documented photographic comparison rather than memory or feel.

The 2017 American Academy of Dermatology AGA guidelines assign finasteride a Level A recommendation for men with androgenetic alopecia, meaning consistent evidence from well-designed randomized controlled trials supports its use [16]. "Finasteride is an effective treatment for male androgenetic alopecia," the guidelines state directly, "and should be offered to men seeking to prevent further hair loss or stimulate regrowth."

At month 12, a man with good adherence who has stabilized should be counseled that he is, in clinical terms, a treatment success, even if he hoped for more aggressive regrowth.